Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration.
Journal Title: Pharmacological Reports - Year 2012, Vol 64, Issue 5
Abstract
Background: Rotenone exposure in rodents provides an interesting model for studying mechanisms of toxin-induced dopaminergic neuronal injury. However, several aspects remain unclear regarding the effects and the accuracy of rotenone as an animal model of Parkinson's disease (PD). In this study, we investigated the motor and depressive-like behaviors associated to neurochemical alterations induced by a novel protocol of rotenone administration. Methods: In the first experiment, we adopted the paw test to characterize an effective dose of rotenone able to promote nigrostriatal toxicity. In the second experiment, control and rotenone 2.5 mg/kg groups were injected (ip) for 10 consecutive days. Results: This test indicated that intraperitonial (ip) rotenone at 2.5 and 5.0 mg/kg promoted a significant neurotoxicity to striatum and nucleus accumbens. However, only 2.5 mg/kg of rotenone was associated to a negligible mortality rate. Open-field tests were conducted on 1, 7, 14 and 21 day after the last day of treatment and showed an important locomotor impairment, confined to 1 and 7 day. Besides, rotenone affected dopamine levels and increased its turnover in the striatum. Modified forced swim test (performed on 22 day) and sucrose preference test (performed on 14 and 21 day) demonstrated that rotenone produced impairments in the swimming and immobility. In parallel, increments in the serotonin and noradrenaline turnovers were observed in the striatum and hippocampus of the rotenone group. Conclusions: These data suggest important participations of serotonin and noradrenaline in depressive-like behaviors induced by rotenone. Thus, it is proposed that the current rotenone protocol provides an improvement regarding the existing rotenonemodels of PD.
Authors and Affiliations
Lívia Morais, Marcelo Lima, Bruno Martynhak, Ronise Santiago, Tatiane Takahashi, Deborah Ariza, Janaína Barbiero, Roberto Andreatini, Maria Vital
Keywords
Related Articles
- EP ID EP87133
- DOI -
- Views 111
- Downloads 0
Morphine-induced place preference affects mRNA expression of G protein α subunits in rat brain.
Background: The conditioned place preference (CPP) test is an animal model serving to assess addictive potential of drugs in which environmental cues become associated with the subjective effects of drugs of abuse. Morph...
Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3.
Background: Acyclovir is acyclic guanosine derivative. Benzylpenicillin (PCG) is a β-lactam antibiotic. The purpose of this study was to investigate the pharmacokinetic drug-drug interaction (DDI) between PCG and acyclov...
Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
Rheumatoid arthritis (RA) is a complex autoimmune disease with clinical prevalence in women. Moreover, women have poorer response to treatment than men. Possible reasons for gender differences in response to treatment co...
Human micro- and macrovessel-derived endothelial cells: a comparative study on the effects of adrenaline and a selective adenosine A(2)-type receptor agonist under normoxic and hypoxic conditions.
Adrenaline is a highly effective stimulator of cyclic AMP (cAMP) production in microvascular endothelial cells (ECs) - HMEC-1, showing only a moderate activity in macrovascular ECs - HUVEC. In both EC preparations, adren...
Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving beta-adrenoceptor linked mechanisms.
Sildenafil, a drug used in the treatment of erectile dysfunction, is a phosphodiesterase 5A inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. In addition to its vascular actions, sildenafil is also k...